PR from Nov.3 -> $EPGL Announces Partnership with
Post# of 1422
Posted On: 12/15/2016 11:56:13 AM
PR from Nov.3 -> $EPGL Announces Partnership with New Technology Company Start-Up
IRVINE, Calif., Nov. 3, 2016 /PRNewswire/ -- EP Global Communications, Inc. (Public OTC: EPGL) announces today that it will partner with a new high technology start-up company that is forming on January 16, 2017 and will manufacture new consumer electronics and medical products.
The new start-up company will begin privately and is being formed by world-class business structure strategists and accountants. It will be positioned for the purpose of a potential IPO on NASDAQ or NYSE in the future.
EPGL shareholders of record on January 16, 2017 will receive equity in the new company up to a percentage equal to their EPGL holdings on that date.
Shareholders who make request for the gift equity at investors@epglmed.com will hold separate shares in both the new private company and EPGL which will continue as a publicly traded OTC Company.
EPGL will continue status-quo as a premier technology R&D company in which Johnson & Johnson Vision Care, Inc. continues to hold first rights of purchase negotiations.
The name of the new company and all further details will be made available in announcements to come in January 2017.
IRVINE, Calif., Nov. 3, 2016 /PRNewswire/ -- EP Global Communications, Inc. (Public OTC: EPGL) announces today that it will partner with a new high technology start-up company that is forming on January 16, 2017 and will manufacture new consumer electronics and medical products.
The new start-up company will begin privately and is being formed by world-class business structure strategists and accountants. It will be positioned for the purpose of a potential IPO on NASDAQ or NYSE in the future.
EPGL shareholders of record on January 16, 2017 will receive equity in the new company up to a percentage equal to their EPGL holdings on that date.
Shareholders who make request for the gift equity at investors@epglmed.com will hold separate shares in both the new private company and EPGL which will continue as a publicly traded OTC Company.
EPGL will continue status-quo as a premier technology R&D company in which Johnson & Johnson Vision Care, Inc. continues to hold first rights of purchase negotiations.
The name of the new company and all further details will be made available in announcements to come in January 2017.
(0)
(0)